Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Efflux-Aware Human BBB Assembloid Assay for Brain-Penetrant Therapeutic Discovery in Medulloblastoma

Award Number: R61NS150150
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2026
PERIOD OF PERFORMANCE END DATE: 08/31/2028

Group Awards By:

View Award Description

Efflux-Aware Human BBB Assembloid Assay for Brain-Penetrant Therapeutic Discovery in Medulloblastoma - Project Summary/Abstract Medulloblastoma (MB) is the most common malignant brain tumor in children and often disseminates early within the central nervous system. Among the four molecular subgroups, Groups 3 and 4 carry the greatest metastatic burden and poorest outcomes. Although digoxin is an approved cardiac glycoside with a well-defined pharmacokinetic (PK) and safety profile and shows activity in Group 3 and Group 4 patient-derived models, translation is limited by its narrow therapeutic index and P-glycoprotein(P-gp)–mediated efflux at the blood brain barrier. We treat radiotherapy as a programmable trigger to localize drug action. Our radiotherapy-activated pro- digoxin chemotypes mask the sugar moiety with N-alkyl-4-picolinium or phenyl-azide carbonate groups to reduce transporter recognition while preserving the lactone required for target engagement; ionizing radiation cleaves the trigger in the treated field to release native digoxin, aiming to raise intratumoral exposure while keeping systemic levels within pediatric therapeutic ranges. The R61 phase will synthesize and analytically qualify two predefined pro-digoxin chemotypes and establish a stability-indicating liquid chromatography–tandem mass spectrometry method to quantify intact pro-drug, released digoxin, and scission products. Using induced pluripotent stem cell–derived brain and vessel organoid assembloids that recapitulate a functional human blood brain barrier, we will quantify radiotherapy-triggered conversion, directional permeability, and P-gp efflux to derive a dose-to-release function and a dosing-to-beam timing window. A focused pilot PK study will confirm brain exposure and lock pharmacodynamic (PD) sampling for Na⁺/K⁺-ATPase target engagement and radiation-linked biomarkers. The R33 phase will implement a preregistered two-by-two design in paired primary and recurrent Group 3 and Group 4 intracranial patient-derived orthotopic xenograft models, using volumetric magnetic resonance imaging to track burden and progression and therapeutic drug monitoring to maintain clinically relevant digoxin-equivalent troughs. Embedded regional bioanalysis will verify in-tissue conversion in irradiated brain, and a focused safety module will monitor cardiac and neurologic tolerance. Critically, R33 will deliver an integrated PK → PD → Efficacy model that links exposure and target engagement to tumor control, identifies the optimal drug-to-radiation schedule and minimal effective duration, and back-translates active mouse exposures to pediatric therapeutic drug-monitoring ranges. By coupling a human neurovascular platform, field-restricted activation chemistry, and quantitative mass spectrometry with rigorous in vivo testing, this program seeks to expand the therapeutic index for children with Group 3 and Group 4 MB and establish a generalizable path from mechanism to schedule to outcome for transporter-limited agents in pediatric neuro-oncology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $500,986 )
2026	2026	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/16/2026	NEW	$500,986
														Subtotal = $500,986

Grand Total All Awards = $500,986

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Efflux-Aware Human BBB Assembloid Assay for Brain-Penetrant Therapeutic Discovery in Medulloblastoma

Award Number: R61NS150150

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2026

PERIOD OF PERFORMANCE END DATE: 08/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer